Rituximab by subcutaneous route

References

• Cartron G, Watier H, Golay J, Solal-Céligny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42
   PubMed Web of Science ®Google Scholar
• Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res 2012;2:676-90
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia 2014;28:1388-95
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3 randomised controlled trial. Lancet 2011;377:42-51
   PubMed Web of Science ®Google Scholar
• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma. Treatment approaches in the molecular era. Nat Rev Clin Oncol 2014;11:12-23
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88
   PubMed Web of Science ®Google Scholar
• Golay J, Semenzato G, Rambaldi A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 2013;5:826-37
   PubMed Web of Science ®Google Scholar
• Plosker GL, Figgit DP. Rituximab: a review of its use in non-Hodgkin’s lymphomas and chronic lymphocytic leukemia. Drugs 2003;63:803-43
   PubMed Web of Science ®Google Scholar
• Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 2010;14:10-21
   PubMedGoogle Scholar
• Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427-40
   PubMed Web of Science ®Google Scholar
• Shpilberg O, Jackish C. Subcutaneous administration of rituximab (Mabthera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer 2013;109:1556-61
   PubMed Web of Science ®Google Scholar
• Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive stage I-III breast cancer (HannaH study). A phase 3 open-label, multicenter, randomized trial. Lancet Oncol 2012;13:869-78
   PubMed Web of Science ®Google Scholar
• Bittner B, Richter WF, Hourcad-Potelleret F, et al. Non-clinical pharmacokinetic/pharmacodynamics and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res 2014;64:569-75
   Google Scholar
• Kagan L, Turner MR, Balu-Lyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 2012;29:490-9
   PubMedGoogle Scholar
• Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma. J Clin Oncol 2014;32:1782-91
   PubMed Web of Science ®Google Scholar
• Velagapudi R, Noertershauser P, Awni W, et al. Bioavailability of adalimumab following subcutaneous injections in rheumatoid arthritis. Clin Pharmacol Ther 2005;77:P84
   Google Scholar
• A pharmacokinetic study of subcutaneous and intravenous MabThera (rituximab) in patients with follicular lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00930514
   Google Scholar
• A study of MabThera (rituximab) subcutaneous vs. MabThera (rituximab) intravenous in patients with follicular non-Hodgkin’s lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01200758
   Google Scholar
• Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomized phase 3 study. Lancet Oncol 2014;15:343-52
   PubMed Web of Science ®Google Scholar
• A study to compare subcutaneous versus intravenous MabThera (rituximab) in combination with chemotherapy in patients with chronic lymphocytic leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01292603
   Google Scholar
• Assouline S, Buccheri V, Delmer A, et al. Non-inferior pharmacokinetics with comparable safety and response rates for subcutaneous (SC) compared with intravenous (IV) rituximab in combination with fludarabine and cyclophosphamide (FC) in patients with untreated chronic lymphocytic leukemia (CLL): part 2 of the Phase 1b SAWYER study. Proceedings of the 56th ASH meeting 2014, San Francisco; A1995
   Google Scholar
• Mao C.P, Brovarney MR, Dabbagh K, et al. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One 2013;8:e80533
   PubMed Web of Science ®Google Scholar
• Rule S, Briones J, Carella AM, et al. A randomized comparison of maintenance therapy with subcutaneous rituximab for 2 years versus until progression in patients with indolent non-Hodgkin’s lymphoma: interim safety data from the Mabcute study. Proceedings of the 55th ASH annual meeting 2013, New Orleans; A3052
   Google Scholar
• A study comparing maintenance subcutaneous MabThera/rituxan (rituximab) with observation only in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma who had responded to MabThera-based immunochemotherapy induction and two years of maintenance with subcutaneous MabThera. Available from: https://clinicaltrials.gov/ct2/show/NCT01461928
   Google Scholar
• Pivot X, Gligorov J, Müller V, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol 2014;25:1979-87
   PubMed Web of Science ®Google Scholar
• De Cock E, Kritikou P, Tao S, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: final analysis from a time-and-motion study in 8 countries. Proceedings of the 55th ASH annual meeting 2013, New Orleans; A1724
   Google Scholar
• Rule S, Collins GP, Samanta K, et al. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma : a time and motion study in the United Kingdom. J Med Econ 2014;17:459-68
   PubMedGoogle Scholar